文献速递肥胖与代谢综合征糖尿病

SELECT试验:司美格鲁肽峰值体重下降的预测因素

Predictors of Peak Body Weight Loss With Semaglutide in the SELECT Trial.
PubMed 文献 · Diabetes Care · 2026-09-24

SELECT试验预设分析纳入7594例持续使用司美格鲁肽≥1年的超重/肥胖合并动脉粥样硬化性心血管疾病成人,中位峰值体重下降12.5%,但基线特征仅预测不足10%的变异,女性及更高剂量与更大体重下降相关。

要点

  • 司美格鲁肽中位峰值体重下降12.5%,中位达峰时间19个月。
  • 基线临床特征对峰值体重下降的预测能力有限(<10%变异)。
  • 女性及最高剂量2.4 mg与更大峰值体重下降相关。

核心结论

  • 基线临床特征无法预测司美格鲁肽治疗后的峰值体重下降幅度。
  • 个体反应差异可能归因于未测量的生物学、行为或遗传因素。
  • 女性和使用最高剂量司美格鲁肽者体重下降幅度最大。

研究设计与样本

  • SELECT试验的预设分析,评估司美格鲁肽对超重/肥胖合并动脉粥样硬化性心血管疾病成人的心血管获益。
  • 纳入7594例随机分配至司美格鲁肽且持续治疗至少1年的参与者(占司美格鲁肽组86.3%)。
  • 采用普通最小二乘法估计的一般线性模型评估基线特征对峰值体重下降百分比的预测作用。

主要发现

  • 中位峰值体重下降为12.5%(IQR 7.9-17.9),中位达峰时间19个月(IQR 10-30)。
  • 全模型预测峰值体重下降变异不足10%,其中女性性别解释约8%的变异(占模型85.3%)。
  • 最高剂量0.24 mg与2.4 mg组的中位峰值体重下降分别为6.0%(IQR 1.9-10.9)和13.3%(IQR 9.0-18.4)。
  • 女性中位峰值体重下降16.6%(IQR 10.9-23.4),男性为12.4%(IQR 8.4-16.9)。

临床怎么用

  • 不应基于基线临床特征预测个体使用司美格鲁肽的体重下降幅度。
  • 女性及使用最高剂量2.4 mg的患者可能获得更大幅度的体重下降。

局限性

  • 分析仅纳入持续治疗至少1年的参与者,可能引入选择偏倚。
  • 未测量因素(生物学、行为、遗传)可能解释大部分个体反应差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate whether clinically available baseline characteristics predict peak percentage body weight loss (%BWL) achieved with chronic use of semaglutide. RESEARCH DESIGN AND METHODS: SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity Trial) evaluated the cardiovascular benefits of semaglutide in adults (mean age 62, 72% men) with obesity and preexisting atherosclerotic disease without diabetes. This prespecified analysis evaluated participants randomized to semaglutide who continued treatment for a minimum of 1 year. Baseline demographics, medical history, laboratory variables, and clinical measurements were candidate predictors of peak %BWL evaluated in a general linear model estimated with ordinary least squares. RESULTS: Among the 7,594 SELECT participants continuously treated with semaglutide for ≥1 year (representing 86.3% of those randomized to semaglutide), median peak %BWL was 12.5% (interquartile range [IQR] 7.9-17.9), achieved after a median of 19 months (IQR 10-30) of treatment. The full model predicted <10% of the variability in peak %BWL; female sex accounted for 85.3% of this model (explaining ≈8% of the variability). Semaglutide dose was associated with peak %BWL (median 6.0% [IQR 1.9-10.9] vs. 13.3% [IQR 9.0-18.4] for those with a maximum dose of 0.24 mg vs. 2.4 mg). The highest median peak %BWL was achieved by women (16.6% [IQR 10.9-23.4]) versus men (12.4% [IQR 8.4-16.9]). CONCLUSIONS: The peak amount of weight loss expected following initiation of semaglutide cannot be predicted based on clinically available baseline characteristics; unmeasured biological, behavioral, or genetic differences are likely responsible for variability in individual response. Women treated with the highest dose of semaglutide experienced the largest %BWL.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Lingvay I, Kushner RF, Kaul U, et al. Predictors of Peak Body Weight Loss With Semaglutide in the SELECT Trial. Diabetes Care. 2026. PMID: 42782193. doi:10.2337/dc26-0784

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。